Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 5/20 | 0.48 |
| ▸ | CSF1R | P07333 | 3/20 | 0.48 |
| ▸ | KIT | P10721 | 2/20 | 0.48 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | FLT4 | P35916 | 5/20 | 0.46 |
| ▸ | FLT3 | P36888 | 4/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3428927 | 0.98 | AURKA (0.49) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2798384 | 0.94 | PDGFRB (0.46) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL4611101 | 0.94 | PDGFRB (0.46) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL4926567 | 0.92 | PDGFRB (0.46) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2798252 | 0.88 | AURKA (0.53) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3427294 | 0.86 | PDGFRB (0.58) | AURKAPDGFRBCSF1RKITPDGFRA | |
| Hydrochloric Acid SCHEMBL2799704 | 0.86 | AURKA (0.50) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL3429377 | 0.86 | AURKA (0.52) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2050019 | 0.85 | AURKA (0.59) | AURKAPDGFRBCSF1RKITPDGFRA | |
| SCHEMBL2053169 | 0.85 | AURKA (0.53) | AURKAPDGFRBCSF1RKITPDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2010-07-01 | — | — | US | claimed |
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB | 2010-07-01 | — | — | US | disclosed |
| EP-1979344-A2 | N-(2,3-DIFLUOROPHENYL)-2-[4-({7-METHOXY-5-[(2R)-PIPERIDIN.-2-YLMETHOXY]QUINAZOLIN-4-YL}AMINO)-1H-PYRAZOL-1-YL]ACETAMIDE AND N-(2,3-DIFLUOROPHENYL)-2-[4-({7-ETHOXY-5-[(2R)-PIPERIDIN.-2-YLMETHOXY]QUINAZOLIN-4-YL}AMINO)-1H-PYRAZOL-1-YL]ACETAMIDE FOR USE IN THE TREATMENT OF DISEASE | AstraZeneca AB (SE) | 2008-10-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168143-A1 | QUINAZOLINE DERIVATIVES | CCNI, NQO2, MKI67 | AURKA 342/4885PDGFRB 2351/4885CSF1R 2440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.